Engineered Polymersomes for the Treatment of Fish Odor Syndrome: A First Randomized Double Blind Olfactory Study

Abstract Trimethylamine (TMA) is a metabolite overtly present in patients suffering from trimethylaminuria (TMAU), a rare genetic disorder characterized by a strong “fishy” body odor. To date, no approved pharmacological treatment to sequester excess TMA on the skin of patients exists. Here, transme...

Full description

Bibliographic Details
Main Authors: Aaron C. Schmidt, Erik R. Hebels, Charlotte Weitzel, Anna Kletzmayr, Yinyin Bao, Christian Steuer, Jean‐Christophe Leroux
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Advanced Science
Subjects:
Online Access:https://doi.org/10.1002/advs.201903697
_version_ 1818497689583616000
author Aaron C. Schmidt
Erik R. Hebels
Charlotte Weitzel
Anna Kletzmayr
Yinyin Bao
Christian Steuer
Jean‐Christophe Leroux
author_facet Aaron C. Schmidt
Erik R. Hebels
Charlotte Weitzel
Anna Kletzmayr
Yinyin Bao
Christian Steuer
Jean‐Christophe Leroux
author_sort Aaron C. Schmidt
collection DOAJ
description Abstract Trimethylamine (TMA) is a metabolite overtly present in patients suffering from trimethylaminuria (TMAU), a rare genetic disorder characterized by a strong “fishy” body odor. To date, no approved pharmacological treatment to sequester excess TMA on the skin of patients exists. Here, transmembrane pH gradient poly(isoprene)‐block‐poly(ethylene glycol) (PI‐b‐PEG) polymersomes are investigated for the topical removal of TMA. PI‐b‐PEG amphiphiles of varying chain length are synthesized and evaluated for their ability to form vesicular structures in aqueous media. The optimization of the PI/PEG ratio of transmembrane pH gradient polymersomes allows for the rapid and efficient capture of TMA both in solution and after incorporation into a topical hydrogel matrix at the pH of the skin. A subsequent double blind olfactory study reveals a significant decrease in perceived odor intensity after application of the polymersome‐based formulation on artificial skin substrates that has been incubated in TMA‐containing medium. This simple and novel approach has the potential to ease the burden of people suffering from TMAU.
first_indexed 2024-12-10T18:48:23Z
format Article
id doaj.art-7e9a60f712064193a0f527e7acffb4d6
institution Directory Open Access Journal
issn 2198-3844
language English
last_indexed 2024-12-10T18:48:23Z
publishDate 2020-04-01
publisher Wiley
record_format Article
series Advanced Science
spelling doaj.art-7e9a60f712064193a0f527e7acffb4d62022-12-22T01:37:25ZengWileyAdvanced Science2198-38442020-04-0178n/an/a10.1002/advs.201903697Engineered Polymersomes for the Treatment of Fish Odor Syndrome: A First Randomized Double Blind Olfactory StudyAaron C. Schmidt0Erik R. Hebels1Charlotte Weitzel2Anna Kletzmayr3Yinyin Bao4Christian Steuer5Jean‐Christophe Leroux6Institute of Pharmaceutical Sciences Department of Chemistry and Applied Biosciences ETH Zurich 8093 Zurich SwitzerlandInstitute of Pharmaceutical Sciences Department of Chemistry and Applied Biosciences ETH Zurich 8093 Zurich SwitzerlandInstitute of Pharmaceutical Sciences Department of Chemistry and Applied Biosciences ETH Zurich 8093 Zurich SwitzerlandInstitute of Pharmaceutical Sciences Department of Chemistry and Applied Biosciences ETH Zurich 8093 Zurich SwitzerlandInstitute of Pharmaceutical Sciences Department of Chemistry and Applied Biosciences ETH Zurich 8093 Zurich SwitzerlandInstitute of Pharmaceutical Sciences Department of Chemistry and Applied Biosciences ETH Zurich 8093 Zurich SwitzerlandInstitute of Pharmaceutical Sciences Department of Chemistry and Applied Biosciences ETH Zurich 8093 Zurich SwitzerlandAbstract Trimethylamine (TMA) is a metabolite overtly present in patients suffering from trimethylaminuria (TMAU), a rare genetic disorder characterized by a strong “fishy” body odor. To date, no approved pharmacological treatment to sequester excess TMA on the skin of patients exists. Here, transmembrane pH gradient poly(isoprene)‐block‐poly(ethylene glycol) (PI‐b‐PEG) polymersomes are investigated for the topical removal of TMA. PI‐b‐PEG amphiphiles of varying chain length are synthesized and evaluated for their ability to form vesicular structures in aqueous media. The optimization of the PI/PEG ratio of transmembrane pH gradient polymersomes allows for the rapid and efficient capture of TMA both in solution and after incorporation into a topical hydrogel matrix at the pH of the skin. A subsequent double blind olfactory study reveals a significant decrease in perceived odor intensity after application of the polymersome‐based formulation on artificial skin substrates that has been incubated in TMA‐containing medium. This simple and novel approach has the potential to ease the burden of people suffering from TMAU.https://doi.org/10.1002/advs.201903697biodetoxificationengineered polymersomesfish odor syndrometrimethylaminetrimethylaminuria
spellingShingle Aaron C. Schmidt
Erik R. Hebels
Charlotte Weitzel
Anna Kletzmayr
Yinyin Bao
Christian Steuer
Jean‐Christophe Leroux
Engineered Polymersomes for the Treatment of Fish Odor Syndrome: A First Randomized Double Blind Olfactory Study
Advanced Science
biodetoxification
engineered polymersomes
fish odor syndrome
trimethylamine
trimethylaminuria
title Engineered Polymersomes for the Treatment of Fish Odor Syndrome: A First Randomized Double Blind Olfactory Study
title_full Engineered Polymersomes for the Treatment of Fish Odor Syndrome: A First Randomized Double Blind Olfactory Study
title_fullStr Engineered Polymersomes for the Treatment of Fish Odor Syndrome: A First Randomized Double Blind Olfactory Study
title_full_unstemmed Engineered Polymersomes for the Treatment of Fish Odor Syndrome: A First Randomized Double Blind Olfactory Study
title_short Engineered Polymersomes for the Treatment of Fish Odor Syndrome: A First Randomized Double Blind Olfactory Study
title_sort engineered polymersomes for the treatment of fish odor syndrome a first randomized double blind olfactory study
topic biodetoxification
engineered polymersomes
fish odor syndrome
trimethylamine
trimethylaminuria
url https://doi.org/10.1002/advs.201903697
work_keys_str_mv AT aaroncschmidt engineeredpolymersomesforthetreatmentoffishodorsyndromeafirstrandomizeddoubleblindolfactorystudy
AT erikrhebels engineeredpolymersomesforthetreatmentoffishodorsyndromeafirstrandomizeddoubleblindolfactorystudy
AT charlotteweitzel engineeredpolymersomesforthetreatmentoffishodorsyndromeafirstrandomizeddoubleblindolfactorystudy
AT annakletzmayr engineeredpolymersomesforthetreatmentoffishodorsyndromeafirstrandomizeddoubleblindolfactorystudy
AT yinyinbao engineeredpolymersomesforthetreatmentoffishodorsyndromeafirstrandomizeddoubleblindolfactorystudy
AT christiansteuer engineeredpolymersomesforthetreatmentoffishodorsyndromeafirstrandomizeddoubleblindolfactorystudy
AT jeanchristopheleroux engineeredpolymersomesforthetreatmentoffishodorsyndromeafirstrandomizeddoubleblindolfactorystudy